CLINICAL TRIALS PROFILE FOR VASOPRESSIN
✉ Email this page to a colleague
All Clinical Trials for vasopressin
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004360 ↗ | Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus | Completed | Northwestern University | 1995-09-01 | OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus. | |
| NCT00004360 ↗ | Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus | Completed | National Center for Research Resources (NCRR) | 1995-09-01 | OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus. | |
| NCT00004363 ↗ | Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus | Completed | Northwestern University | 1995-12-01 | OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently. | |
| NCT00004363 ↗ | Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus | Completed | National Center for Research Resources (NCRR) | 1995-12-01 | OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently. | |
| NCT00004364 ↗ | Study of Novel Types of Familial Diabetes Insipidus | Unknown status | Northwestern University | 1995-12-01 | OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI. | |
| NCT00004364 ↗ | Study of Novel Types of Familial Diabetes Insipidus | Unknown status | National Center for Research Resources (NCRR) | 1995-12-01 | OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI. | |
| NCT00032734 ↗ | Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion | Completed | Sanofi | Phase 2 | 2001-06-01 | The study is designed to assess the efficacy of an investigational drug called SR121463B (vasopressin receptor antagonist) in the treatment of low levels of sodium in the blood associated with the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH). This double blind period study is followed by 2 open label extension studies with flexible doses of satavaptan. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for vasopressin
Condition Name
Clinical Trial Locations for vasopressin
Trials by Country
Clinical Trial Progress for vasopressin
Clinical Trial Phase
Clinical Trial Sponsors for vasopressin
Sponsor Name
